Briefing: Potential Impacts of CER on Patient Access

Global head-to-head trials for wet age-related macular degeneration (AMD) are currently underway and raising the issue of how their results will impact innovation and patient access. This briefing will educate and inform stakeholders, advocates, and thought leaders on what needs to be done to ensure that CER reduces health care costs without compromising quality of care. Topics to be covered include:

The Aging Population and Importance Patient Access
Daniel Perry, Alliance for Aging Research
The wAMD Trials and Impact of w/AMD
Barbara McLaughlan, AMDAI/RNIB – Presentation
Andrea Densham, Prevent Blindness America – Presentation
Effects on Global Policy
Jonathan Ortmans, PFI – Presentation
The Role of Stakeholders
Chris Henshall, HTAi